# OnCo record sevilla (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sevilla/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sevilla", "NCT06529718" ;
  schema:name "SEVILLA"@en ;
  schema:description "SEVILLA is a French-British randomised trial comparing ivonescimab, an antibody that blocks both PD-1 and the blood vessel signal VEGF, with FOLFOX chemotherapy as second-line treatment for bile duct and gallbladder cancer. University College London is the UK site."@en ;
  schema:url <https://onco.cc/trials/sevilla/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06529718> ;
  onco:status "recruiting" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/folfox/> ;
  onco:institutions <https://onco.cc/institutions/uclh/> .